|
所属 |
附属病院 第三内科 |
職務経歴（学内） 【 表示 ／ 非表示 】
-
2024年04月-継続中
秋田大学 附属病院 第三内科 講師
-
2022年04月-2024年03月
秋田大学 附属病院 第三内科 助教
-
2020年10月-2022年03月
秋田大学 附属病院 中央検査部 助教
学位論文 【 表示 ／ 非表示 】
-
Phase II clinical trial of lenalidomide and dexamethasone therapy in Japanese elderly patients with newly diagnosed multiple myeloma to determine optimal plasma concentration of lenalidomide
小林 敬宏
Therapeutic Drug Monitoring 2018年09月 [査読有り]
国内共著
研究等業績 【 表示 ／ 非表示 】
-
Sato H.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 90 ( 3 ) 279 - 284 2022年09月
-
Jiro Kikuchi, Nobuyuki Kodama, Masataka Takeshita, Sho Ikeda, Takahiro Kobayashi, Yoshiaki Kuroda, Michihiro Uchiyama, Naoki Osada, Bjarne Bogen, Hiroshi Yasui, Naoto Takahashi, Akiyoshi Miwa, Yusuke Furukawa
Blood Advances ( American Society of Hematology ) 2022年08月
Extramedullary disease (EMD) is known to be associated with chemoresistance and poor prognosis in multiple myeloma (MM); however, the mechanisms of its development are not fully understood. Elucidating the mechanism of EMD development and its therapeutic targeting would greatly contribute to further improvement of treatment outcome in MM patients. Here, we show that bone marrow stroma cell-derived hyaluronan elicits homophilic interactions of MM cells by binding to surface CD44, especially long-stretch variants, under physiological shear stress and generates cell clusters that might develop into EMD. We recapitulated the development of EMD via administration of hyaluronan in a syngeneic murine MM model in a CD44-dependent manner. Hyaluronan-induced MM cell clusters exhibited the specific resistance to proteasome inhibitors (PIs) in vitro and in murine models via γ-secretase-mediated cleavage of the intracellular domains of CD44, which in turn transactivated PI resistance-inducible genes. Treatment of hyaluronan-injected mice with anti-CD44 antibody or γ-secretase inhibitors readily suppressed the development of EMD from transplanted MM cells and significantly prolonged the survival of recipients by overcoming PI resistance. The hyaluronan-CD44 axis represents a novel pathway to trigger EMD development and could be a target of the prediction, prevention, and treatment of EMD in MM patients.
-
[Postmortem diagnosis of intravascular large B-cell lymphoma after atraumatic splenic rupture due to splenic infiltration].
Wataru Kuroki, Takahiro Kobayashi, Michinobu Umakoshi, Akihiro Kitadate, Chihiro Imaizumi, Masaya Saito, Isuzu Kobayashi, Masumi Fujishima, Naohito Fujishima, Tomoko Yoshioka, Akiteru Goto, Naoto Takahashi
[Rinsho ketsueki] The Japanese journal of clinical hematology ( 一般社団法人 日本血液学会 ) 63 ( 6 ) 523 - 529 2022年
Atraumatic splenic rupture (ASR) is a rare but fatal complication of malignant lymphoma. However, only one case of intravascular large B-cell lymphoma (IVLBCL)-related ASR (IVLBCL-ASR) has previously been reported, and the mechanism of IVLBCL-ASR is unknown. We present the case of a 78-year-old man who died unexpectedly and was diagnosed with IVLBCL-ASR pathologically by autopsy. A massive intraperitoneal hemorrhage and four lacerations on the splenic surface were discovered during the autopsy. CD20-positive lymphoma cells that infiltrated into small vessels were highly concentrated in the center of the spleen and were only slightly distributed in the lacerations on the splenic surface. Therefore, increased intrasplenic pressure due to lymphoma cell proliferation was identified as the cause of ASR. The patient had undergone 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for tongue cancer evaluation 3 months earlier, and positive uptake was found in the right adrenal gland, where lymphoma cell infiltration was confirmed by the autopsy. Our findings suggest that clinicians should be aware that the advanced stage of IVLBCL can cause fatal ASR via increased intrasplenic pressure. Therefore, early diagnosis and early treatment intervention are desirable to prevent the onset of IVLBCL-ASR, and 18F-FDG PET/CT is useful for the early diagnosis of IVLBCL.
-
IGL/MYC再構成を有し、かつCD138の発現を伴うB細胞性リンパ芽球性白血病(Precursor B-lymphoblastic leukemia with IGL/MYC rearrangement and CD138 expression)
倉橋 保奈実, 山下 鷹也, 北舘 明宏, 道下 吉広, 川端 良成, 北林 淳, 松本 奈津美, 齋藤 雅也, 小林 敬宏, 藤島 直仁, 亀岡 吉弘, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS3 - 3 2021年09月
-
高腫瘍量濾胞性リンパ腫における治療前PET/CTを用いたTLGの予後予測因子としての有用性(Prognostic value of baseline total lesion glycolysis in high-tumor-burden follicular lymphoma)
黒木 航, 北舘 明宏, 山下 鷹也, 小林 敬宏, 池田 翔, 奈良 美保, 鵜生川 久美, 藤島 直仁, 吉岡 智子, 石山 公一, 亀岡 吉弘, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS1 - 1 2021年09月
◆その他【 表示 ／ 非表示 】
科研費（文科省・学振）獲得実績 【 表示 ／ 非表示 】
-
多発性骨髄腫におけるレナリドミドのNK細胞感受性を決定する要因の探索
若手研究
研究期間: 2020年04月 - 2023年03月 代表者: 小林敬宏